Spotlight On: Biosimilar Litigations - April 2026

Why It Matters

Understanding the scope of covered litigation helps pharmaceutical companies assess litigation risk and allocate resources efficiently, directly influencing product launch timelines and market entry strategies.

Key Takeaways

• Biosimilar disputes involve reference product sponsors and biosimilar manufacturers.
• Litigations also arise between competing biosimilar developers over patent claims.
• Manufacturing‑process patents are excluded from this update’s scope.
• Reference‑product sponsor disputes are not covered in this analysis.
• Legal counsel advises case‑by‑case review despite the general overview.

Pulse Analysis

Biosimilar litigation has become a pivotal battleground as biologics lose patent protection and generic‑like competitors vie for market share. The April 2026 update from Venable LLP draws a clear line around which disputes are monitored, focusing on direct conflicts between biosimilar applicants and the original biologic’s sponsor. By excluding intra‑reference sponsor fights and broad manufacturing patents, the memo narrows attention to the most commercially consequential cases, allowing companies to prioritize monitoring of patent infringement suits that could delay product launches.

The practical impact of this delineation is significant for both incumbents and newcomers. Reference‑product sponsors, such as major biotech firms, can anticipate the timing and intensity of challenges from biosimilar developers, shaping their settlement strategies and patent‑pool negotiations. Meanwhile, biosimilar manufacturers gain insight into which patent pillars—typically composition‑of‑matter or method‑of‑use claims—are most likely to trigger litigation, informing their freedom‑to‑operate analyses and R&D roadmaps. Excluding manufacturing‑process patents, which often affect multiple products, reduces noise and highlights the core intellectual‑property barriers that directly affect market entry.

Looking ahead, the evolving litigation landscape will influence pricing dynamics and patient access to affordable biologics. As courts continue to interpret the Biologics Price Competition and Innovation Act, stakeholders must stay agile, leveraging specialized counsel to navigate case‑by‑case nuances. The focused scope of the April 2026 briefing equips industry leaders with a clearer risk picture, enabling smarter investment decisions and more strategic patent‑portfolio management in a rapidly maturing biosimilar market.